Study Validates Wiley Protocol

Bio-identical hormones can only be termed bio-identical if they mimic not only those chemically found in the body, but also imitate the natural biological process as well. A woman’s body does not produce hormones statically (the same amount every day) but in a undulating and changing rhythm throughout a 28 day cycle. In order to be biomimetic and truly natural, new findings show that the therapy should produce a menstrual cycle.

New research sheds fresh light on healthy hormone replacement therapy (HRT), suggesting that women must cycle their hormones and have a menstrual bleed to be truly safe from negative cardiovascular events. According to a recent Danish study, a combined cyclic regimen with monthly bleeding creates a lower cardiovascular risk for women than continuous-combined estrogen/progesterone/progestin therapy, which does not cause a menstrual bleed. The study also found that overall there was no increased risk of heart attacks in current users of HRT compared to women who had never taken hormones.

This research is significant validation of the value of cyclical (estrogen, followed by a combination of estrogen and progesterone) hormone therapy and that biomimetic hormone restoration therapy (BHRT) may actually be safer than statically dosed continuous-combined alternatives, whether bio-identical or synthetic.

According to the principal investigator of this research, *Dr Ellen Løkkegaard, a gynecologist at the Rigshospitalet in Copenhagen, Denmark, “The main message is that when hormone therapy is indicated for a woman, then a cyclic combined regimen should be preferred, and that application via the skin or the vagina is associated with a decreased risk of myocardial infarction.” The observational study, the largest to look at the effects of HRT since the Women's Health Initiative (WHI) trial in 1991, followed 698,098 healthy Danish women, aged 51-69

A Clinical Study

Women deserve hormone restoration that is proven to be safe and reliable. A new study, Bio-identical Hormones On Trial, or B.H.O.T., will soon begin at the College of Nursing and Health Sciences at the University of Texas , Tyler . The principal objective of the study will be to examine clinical outcomes and quality of life indicators of patients receiving BHRT at 10 to 12 primary care provider's practices. This study will be the first of its kind to track and quantify outcomes based on dosing and patterns of administration of BHRT.

Biomimetic Hormone Restoration and Healthcare Costs

Using a true biomimetic hormone restoration therapy, relief from many menopausal symptoms, such as improved sleep could allow women to live happier and more productive lives. Medicare and other insurance reimbursements for constant doctor visits and endless prescriptions and procedures would be reduced. Quality of life would improve for most symptomatic women and many more women would never have to experience the debilitating effects of being without their hormones.

Every day, forward thinking doctors, now leery of the “Standard of Care” approved synthetics, are choosing safe, effective, biomimetic hormone restoration. By 2030 there will be 57.8 million baby boomers between the ages of 66 and 84 living with many of these health issues. There’s a possibility that those who choose rhythmic replacement, the Wiley Protocol, could age to a healthier more graceful tune.